LOGIN  |  REGISTER
Cue Biopharma
Recursion

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2025

February 26, 2025 | Last Trade: US$96.32 1.12 1.18

WARSAW, Ind., Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2025. The cash dividend of $0.24 per share is payable on or about April 30, 2025 to stockholders of record as of the close of business on March 31, 2025.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

Media

Heather Zoumas-Lubeski
445-248-0577
This email address is being protected from spambots. You need JavaScript enabled to view it.
';document.getElementById('cloak5b99ffea710b916fd9f34a78a3188329').innerHTML += ''+addy_text5b99ffea710b916fd9f34a78a3188329+'<\/a>';  

Investors

David DeMartino
646-531-6115
This email address is being protected from spambots. You need JavaScript enabled to view it.
';document.getElementById('cloak88384a965c4a493be6f3a6393a9035c3').innerHTML += ''+addy_text88384a965c4a493be6f3a6393a9035c3+'<\/a>';

 

Zach Weiner
908-591-6955
This email address is being protected from spambots. You need JavaScript enabled to view it.
';document.getElementById('cloak657a5107e1cae5ee00107caf68109eae').innerHTML += ''+addy_text657a5107e1cae5ee00107caf68109eae+'<\/a>';

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page